Docetaxel

small molecule

Identifier: CI-DRUG-00000190
Entity page: /drug/docetaxel ↗
Edges: 2,133

Neighbours: 22 cancers15 genes13 variants10 trials15 approvals
Drawn: 60 of 75 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Docetaxel approved for …APPROVED_FOR29 of 35show all (up to 200)
→ approved for	Head and Neck Squamous Cell Carcinomasubtype 8 source records aggregated	supports	FDA ORIG	Head and Neck Squamous Cell Carcinoma	8	Regulatory	openfda	graph →
→ approved for

→ approved for

EMA · EU · 2015Breast cancer Taxespira in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with: operable node-positive breast cancer; operable node-negative breast cancer. For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer. Taxespira in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Taxespira monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Taxespira combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease. Taxespira in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Non-small cell lung cancer Taxespira indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy. Taxespira in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition. Prostate cancer Taxespira in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer. Gastric adenocarcinoma Taxespira in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease. Head and neck cancer Taxespira in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

EMA (EU) · withdrawn · 2015-08-28 · Breast cancer Taxespira in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with: oper…

—

withdrawn

not mapped

Regulatory

ema

open ↗

→ approved for

EMA · EU · 2012Breast cancer Docetaxel Kabi in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with: operable node-positive breast cancer; operable node-negative breast cancer. For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer. Docetaxel Kabi in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Docetaxel Kabi monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Docetaxel Kabi in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Docetaxel Kabi in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Non-small-cell lung cancer Docetaxel Kabi is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy. Docetaxel Kabi in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition. Prostate cancer Docetaxel Kabi in combination with prednisone or prednisolone is indicated for the treatment of patients with castration-resistant metastatic prostate cancer. Docetaxel Kabi in combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer. Gastric adenocarcinoma Docetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease. Head and neck cancer Docetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

EMA (EU) · approved · 2012-05-22 · Breast cancer Docetaxel Kabi in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:…

—

approved

not mapped

Regulatory

ema

open ↗

→ approved for

EMA · EU · 2012Breast cancer Docetaxel Accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with: operable node-positive breast cancer; operable node-negative breast cancer. For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer. Docetaxel Accord in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Docetaxel Accord monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Docetaxel Accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Docetaxel Accord in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Non-small-cell lung cancer Docetaxel Accord is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy. Docetaxel Accord in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition. Prostate cancer Docetaxel Accord in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer. Gastric adenocarcinoma Docetaxel Accord in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease. Head and neck cancer Docetaxel Accord in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

EMA (EU) · approved · 2012-05-22 · Breast cancer Docetaxel Accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients wit…

—

approved

not mapped

Regulatory

ema

open ↗

→ approved for

EMA · EU · 2010Breast cancer Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. Docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Docetaxel monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease. Docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Non-small cell lung cancer Docetaxel is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy. Docetaxel in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition. Prostate cancer Docetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer. Gastric adenocarcinoma Docetaxel in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease. Head and neck cancer Docetaxel in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

EMA (EU) · withdrawn · 2010-05-10 · Breast cancer Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with opera…

—

withdrawn

not mapped

Regulatory

ema

open ↗

Docetaxel predicts response to …PREDICTS_RESPONSE_TO15 of 19show all (up to 200)
← predicts response to	KRAS Mutationother	resistance	A	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
← predicts response to	KRAS Mutationother 2 source records aggregated	sensitivity	B	Lung Non-Small Cell Carcinoma	2	Curated	civic	graph →
← predicts response to	ERBB2 Amplificationamplification 2 source records aggregated	sensitivity	B	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
← predicts response to	KRAS G12VSNV	sensitivity	B	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
← predicts response to	KRAS Amplificationamplification	sensitivity	B	Cutaneous Melanoma	1	Curated	civic	graph →
← predicts response to	NRAS Mutationother	sensitivity	B	Cutaneous Melanoma	1	Curated	civic	graph →
← predicts response to	KRAS G12CSNV	sensitivity	B	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
← predicts response to	CXCR4 EXPRESSIONexpression	resistance	B	Gastric Adenocarcinoma	1	Curated	civic	graph →
← predicts response to	EGFR VIIIdeletion	resistance	B	Head and Neck Squamous Cell Carcinoma	1	Curated	civic	graph →
← predicts response to	AREG Expressionexpression	resistance	B	Head and Neck Squamous Cell Carcinoma	1	Curated	civic	graph →
← predicts response to	DEFA1 EXPRESSIONexpression	sensitivity	B	Malignant Prostate Neoplasm	1	Curated	civic	graph →
← predicts response to	XRCC1 R194WSNV	sensitivity	B	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
← predicts response to	PTEN Lossdeletion_cna	sensitivity	D	Malignant Gastric Neoplasm	1	Curated	civic	graph →
← predicts response to	PTEN Lossdeletion_cna	resistance	D	Malignant Gastric Neoplasm	1	Curated	civic	graph →
← predicts response to	GAS6 EXPRESSIONexpression	resistance	D	Malignant Prostate Neoplasm	1	Curated	civic	graph →

Docetaxel targets …TARGETS15 of 15
→ targets	TUBB2A	—	INHIBITOR\|STABILISER	—	1	Curated	chembl	graph →
→ targets	TUBB2B	—	INHIBITOR\|STABILISER	—	1	Curated	chembl	graph →
→ targets	TUBB6	—	INHIBITOR\|STABILISER	—	1	Curated	chembl	graph →
→ targets	TUBA1B	—	INHIBITOR\|STABILISER	—	1	Curated	chembl	graph →
→ targets	TUBA1C	—	INHIBITOR\|STABILISER	—	1	Curated	chembl	graph →
→ targets	TUBA3E	—	INHIBITOR\|STABILISER	—	1	Curated	chembl	graph →
→ targets	TUBB	—	INHIBITOR\|STABILISER	—	1	Curated	chembl	graph →
→ targets	TUBB8	—	INHIBITOR\|STABILISER	—	1	Curated	chembl	graph →
→ targets	TUBA1A	—	INHIBITOR\|STABILISER	—	1	Curated	chembl	graph →
→ targets	TUBB4A	—	INHIBITOR\|STABILISER	—	1	Curated	chembl	graph →
→ targets	TUBA3C	—	INHIBITOR\|STABILISER	—	1	Curated	chembl	graph →
→ targets	TUBA4A	—	INHIBITOR\|STABILISER	—	1	Curated	chembl	graph →
→ targets	TUBB3	—	INHIBITOR\|STABILISER	—	1	Curated	chembl	graph →
→ targets	TUBB1	—	INHIBITOR\|STABILISER	—	1	Curated	chembl	graph →
→ targets	TUBB4B	—	INHIBITOR\|STABILISER	—	1	Curated	chembl	graph →

Docetaxel investigated for …INVESTIGATED_FOR15 of 77show all (up to 200)
→ investigated for	Lung Non-Small Cell Carcinomasubtype	supports	A	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype 5 source records aggregated	supports	B	Lung Non-Small Cell Carcinoma	5	Curated	civic	graph →
→ investigated for	Cutaneous Melanomacancer 2 source records aggregated	supports	B	Cutaneous Melanoma	2	Curated	civic	graph →
→ investigated for	Head and Neck Squamous Cell Carcinomasubtype 2 source records aggregated	supports	B	Head and Neck Squamous Cell Carcinoma	2	Curated	civic	graph →
→ investigated for	HER2-Positive Breast Carcinomamolecular_subtype 2 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
→ investigated for	Gastric Adenocarcinomasubtype	supports	B	Gastric Adenocarcinoma	1	Curated	civic	graph →
→ investigated for	Malignant Prostate Neoplasmcancer	supports	B	Malignant Prostate Neoplasm	1	Curated	civic	graph →
→ investigated for	Head and Neck Squamous Cell Carcinomasubtype	unknown	4	Head and Neck Squamous Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Adenocarcinomahistology	unknown	4	Adenocarcinoma	1	Curated	chembl	graph →
→ investigated for	Head and Neck Neoplasmcancer_family	unknown	4	Head and Neck Neoplasm	1	Curated	chembl	graph →
→ investigated for	Prostate Neoplasmsubtype	unknown	4	Prostate Neoplasm	1	Curated	chembl	graph →
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	unknown	4	Lung Non-Small Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Gastric Neoplasmcancer_family	unknown	4	Gastric Neoplasm	1	Curated	chembl	graph →
→ investigated for	Breast Neoplasmcancer_family	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →

Docetaxel investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 258show all (up to 200)
→ investigated in trials for	Malignant Breast Neoplasmcancer_family 317 trials (34 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	317	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 295 trials (68 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	295	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Prostate Neoplasmcancer 207 trials (32 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Prostate Neoplasm	207	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Lung Neoplasm 105 trials (12 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Lung Neoplasm	105	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Gastric Neoplasm 78 trials (14 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Gastric Neoplasm	78	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Head and Neck Neoplasm 65 trials (7 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Head and Neck Neoplasm	65	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 62 trials (19 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	62	Observed	clinicaltrials	graph →
→ investigated in trials for	Breast Neoplasmcancer_family 55 trials (12 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Breast Neoplasm	55	Observed	clinicaltrials	graph →
→ investigated in trials for	Head and Neck Squamous Cell Carcinomasubtype 46 trials (16 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Head and Neck Squamous Cell Carcinoma	46	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Esophageal Neoplasm 38 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Esophageal Neoplasm	38	Observed	clinicaltrials	graph →
→ investigated in trials for	Prostate Neoplasmsubtype 38 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Prostate Neoplasm	38	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Ovarian Neoplasm 37 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Ovarian Neoplasm	37	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Solid Neoplasm 35 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Solid Neoplasm	35	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm 35 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	35	Observed	clinicaltrials	graph →
→ investigated in trials for	Castration-Resistant Prostate Carcinomasubtype 29 trials (13 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Castration-Resistant Prostate Carcinoma	29	Observed	clinicaltrials	graph →

Docetaxel studied in …STUDIED_INderived10 of 1,729show all (up to 200)
→ studied in	NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · 1,729 trials list this drug (321 active)	—	—	Esophageal Neoplasm,Gastric Neoplasm,Gallbladder Neoplasm+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT05901428Phase 3 · recruiting TCb vs EC-T in High Risk ER+/HER2- Breast Cancer · 1,729 trials list this drug (321 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT06780098Phase 2 · recruiting Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) · 1,729 trials list this drug (321 active)	—	—	Lung Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03390504Phase 3 · active not recruiting A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations · 1,729 trials list this drug (321 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT05132075Phase 3 · active not recruiting Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer · 1,729 trials list this drug (321 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05818683Phase 1 · recruiting A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer · 1,729 trials list this drug (321 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT06545955Phase 3 · recruiting A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer · 1,729 trials list this drug (321 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT07225946Phase 3 · recruiting A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer · 1,729 trials list this drug (321 active)	—	—	Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07419295Phase 3 · recruiting A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) · 1,729 trials list this drug (321 active)	—	—	Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT00295893Phase 2 · active not recruiting Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer · 1,729 trials list this drug (321 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths